The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.
BACKGROUND
High-risk surgical patients are at increased risk of fungal infections and candidaemia. Evidence from observational and small randomised controlled studies suggests that prophylactic fluconazole may be effective in reducing fungal infection and mortality. We evaluated the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients.


METHODS
Randomised controlled studies involving the use of fluconazole in immunocompetent high-risk surgical patients from the Cochrane Controlled Trial Register (2005, issue 1) and from the EMBASE and MEDLINE databases (1966-30 April 2005), without any language restriction, were included. Two reviewers reviewed the quality of the studies and performed data extraction independently.


RESULTS
Seven randomised controlled studies with a total of 814 immunocompetent high-risk surgical patients were considered. The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06-0.72, P = 0.01; I2 = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24-0.65, P = 0.0003; I2 = 0%), but was associated with only a trend towards a reduction in hospital mortality (RR = 0.82, 95% CI = 0.62-1.08, P = 0.15; I2 = 7%). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17-0.72, P = 0.004; I2 = 0%). The proportion of patients colonised with or infected with fluconazole-resistant fungi was not significantly different between the fluconazole group and the placebo group (RR = 0.66, 95% CI = 0.22-1.96, P = 0.46; I2 = 0%).


CONCLUSIONS
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients is associated with a reduced incidence of candidaemia but with only a trend towards a reduction in hospital mortality.
Ho
Kwok M
KM
Department of Intensive Care, Royal Perth Hospital, Australia. kwok.ho@health.wa.gov.au
Lipman
Jeffrey
J
Dobb
Geoffrey J
GJ
Webb
Steven A R
SA
D000935:Antifungal Agents / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D007121:Immunocompetence; D009181:Mycoses / Q000276:immunology / Q000517:prevention & control*; D019990:Perioperative Care / Q000379:methods; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control*; D018570:Risk Assessment; D016896:Treatment Outcome
D000935:Antifungal Agents; D015725:Fluconazole